EP2

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 19, 2024
Research, OS, NCI, Mutation, EP4, Gene expression, Immunotherapy, RECIST, Patient, National Cancer Institute, Pembrolizumab, Society, AACR, Bevacizumab, Therapy, Nivolumab, ASCO, EP2, SITC, PFS, Liver cancer, FDA, Pharmaceutical industry

“2023 was a transformative year for Tempest.

Key Points: 
  • “2023 was a transformative year for Tempest.
  • We announced strong positive randomized data showing the benefit of TPST-1120 combination therapy compared to standard-of-care in first-line liver cancer,” said Stephen Brady, president and chief executive officer of Tempest.
  • Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022.
  • Based on current cash and operating plan, Tempest expected to have sufficient resources to fund operations into the second quarter of 2025.

Synopsys Announces New AI-Driven EDA, IP and Systems Design Solutions At SNUG Silicon Valley

Retrieved on: 
Wednesday, March 20, 2024
Cloud, Momentum, CVP, Socs, History, IP, PUF, Microsoft, 4X, Synthetic media, Intel, Webcast, 3D, Software, Ghazi, HAV, Compiler, PPA, Intrinsic and extrinsic properties, RTL, EDA, News, Acquisition, AI, Field-programmable gate array, Architecture, Samsung, AMD, Santa Clara Convention Center, Engineering, UCIe, Stunning, Ecosystem, EP2, SNPS, Generative, TSMC, Video game

SUNNYVALE, Calif., March 20, 2024 /PRNewswire/ -- Today Synopsys, Inc. (Nasdaq: SNPS) kicked off its annual flagship Synopsys User Group (SNUG) conference in Silicon Valley at the Santa Clara Convention Center with a keynote presentation by Synopsys president and CEO Sassine Ghazi. Ghazi discussed the unprecedented innovation opportunities and challenges that technology R&D teams face in this era of pervasive intelligence. He also announced new EDA and IP solutions aimed at maximizing the capabilities of the global technology engineering teams, from silicon to systems, that Synopsys serves.

Key Points: 
  • (Nasdaq: SNPS ) kicked off its annual flagship Synopsys User Group (SNUG) conference in Silicon Valley at the Santa Clara Convention Center with a keynote presentation by Synopsys president and CEO Sassine Ghazi.
  • He also announced new EDA and IP solutions aimed at maximizing the capabilities of the global technology engineering teams, from silicon to systems, that Synopsys serves.
  • The company plans to discuss its growing design IP business during this afternoon's investor meeting, which is co-located with SNUG Silicon Valley.
  • Happening March 20 and 21 in Santa Clara, Calif., SNUG Silicon Valley gathers the global Synopsys design community to discuss technology advancements, challenges, strategic collaborations, and business opportunities.

Vishay Intertechnology’s EP2 Wet Tantalum Capacitor Named as 2023 Elektra Awards Finalist

Retrieved on: 
Thursday, October 12, 2023
VSH, NYSE, DNA, Grosvenor House Hotel, EP2, Vishay Intertechnology, Radar, VDC, Electronics, Electronics Weekly, Telecommunications

Finalists in the “Passive and Electromechanical Product of the Year” category were chosen based on demonstrated technical capabilities that differentiate them from competing products.

Key Points: 
  • Finalists in the “Passive and Electromechanical Product of the Year” category were chosen based on demonstrated technical capabilities that differentiate them from competing products.
  • Offering robust mechanical performance, the capacitor features high vibration (high frequency: 20 g; random: 19.64 g) and mechanical shock (50 g) capabilities.
  • Award winners will be announced at the Elektra Awards Dinner, taking place in London on Nov. 29 at the Grosvenor House Hotel.
  • Serving customers worldwide, Vishay is The DNA of tech.® Vishay Intertechnology, Inc. is a Fortune 1,000 Company listed on the NYSE (VSH).

Visiox Pharma Licenses OMLONTI®

Retrieved on: 
Wednesday, July 19, 2023
Glaucoma, IOP, EP2, House of Santen, Ocular hypertension, Patient, NCE, Growth, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry, New chemical entity

Visiox plans to launch OMLONTI in early 2024, followed by once-daily PDP-716 (brimonidine) 0.35%, positioning the company to become a leader in glaucoma, a disease with significant impact on patients.

Key Points: 
  • Visiox plans to launch OMLONTI in early 2024, followed by once-daily PDP-716 (brimonidine) 0.35%, positioning the company to become a leader in glaucoma, a disease with significant impact on patients.
  • "We believe this is a compelling transaction, as it expands our addressable market opportunity enhancing our long-term growth and profitability."
  • The strategic license provides exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®.
  • Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of OMLONTI® in the U.S.

Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together

Retrieved on: 
Wednesday, July 19, 2023
Biology, EP1, Cancer, American Association for Cancer Research, EP4, PGE2, Therapy, EP2, EP3, HCC, Pharmaceutical industry, Tempest

BRISBANE, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that in vivo and in vitro data on the unique mechanism of TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling, were published in Cancer Research Communications, a journal of the American Association for Cancer Research.

Key Points: 
  • BRISBANE, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that in vivo and in vitro data on the unique mechanism of TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling, were published in Cancer Research Communications, a journal of the American Association for Cancer Research.
  • “While the biology of PGE2 in promoting tumor growth and immune suppression is well established, there are still no approved drugs for cancer that effectively block the prostaglandin pathway,” said Tom Dubensky, Ph.D., president of Tempest.
  • “Our innovation with TPST-1495 shows for the first time the effect of blocking PGE2 signaling through the EP2 and EP4 pro-tumor receptors while maintaining the important anti-tumor signaling of PGE2 through the EP1 and EP3 receptors, which could be an important advance to inhibiting PGE2.
  • Additionally, these results further support what we believe is an innovative and robust pipeline at Tempest that includes TPST-1120, a novel PPAR⍺ antagonist, which has shown early positive data from an ongoing global randomized study in first-line HCC patients.”

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 22, 2023
Patent, AACR, Arm, Therapy, Hepatocellular carcinoma, Roche, RECIST, Cancer, SITC, American Association for Cancer Research, Immunotherapy, EP2, Research, Biomarker, Trial of the century, TREX1, ASCO, American Society of Clinical Oncology, Patient, Annual general meeting, Society for Immunotherapy of Cancer, HCC, EP4, Pembrolizumab, Society, ORR, Nivolumab, Pharmaceutical industry, Tempest

“2022 featured significant milestones for the company, including our first clinical proof of concept data, which was recognized in an oral presentation at ASCO,” said Stephen Brady, chief executive officer of Tempest.

Key Points: 
  • “2022 featured significant milestones for the company, including our first clinical proof of concept data, which was recognized in an oral presentation at ASCO,” said Stephen Brady, chief executive officer of Tempest.
  • TREX1 Inhibitor (preclinical tumor-selective STING pathway activator): presented the first preclinical anti-tumor results with proprietary small molecule TREX1 inhibitor at AACR 2022.
  • Tempest ended the year with $31.2 million in cash and cash equivalents, compared to $51.8 million on December 31, 2021.
  • Based on current cash position and operating plan, Tempest expects to have sufficient resources to fund operations through the second quarter of 2024.

Nextech AR Trades Up To The OTCQX® Best Market

Retrieved on: 
Friday, December 16, 2022
Technology, Metaverse, Hardware, Artificial Intelligence, NTAR, Education, Canadian Securities Exchange, AR, Commerce, Arit Okpo, OTC Markets Group, Student, EP2, OTC, 3D, FSE, Industrial, Legislation, Frankfurt Stock Exchange, CSE, Internationalization of the renminbi, Growth, Iveco Bus, Nex Entertainment, AI, Security (finance), Metaverse

Nextech AR Solutions Corp. (Nextech or the Company) (OTCQX: NEXCF) (CSE: NTAR) (FSE: EP2), a Metaverse Company and leading provider of augmented reality (AR) experience technologies, wayfinding technologies and 3D model services is pleased to announce that its common shares are now trading on the OTCQX Best Market.

Key Points: 
  • Nextech AR Solutions Corp. (Nextech or the Company) (OTCQX: NEXCF) (CSE: NTAR) (FSE: EP2), a Metaverse Company and leading provider of augmented reality (AR) experience technologies, wayfinding technologies and 3D model services is pleased to announce that its common shares are now trading on the OTCQX Best Market.
  • The OTCQX Best Market is the highest market tier of OTC Markets on which 12,000 U.S. and global securities trade.
  • To qualify for OTCQX Best Market, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.
  • Graduating to the OTCQX Best Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer

Retrieved on: 
Thursday, November 10, 2022
Molecule, SAN, GLOBE, PPAR, Annual general meeting, EP4, Immunotherapy, Gene, Neoplasm, Society for Immunotherapy of Cancer, Therapy, Biomarker, Patient, Gene expression, SITC, Celecoxib, EP2, PGE2, Society, Pharmaceutical industry, Medical imaging, Cancer, Tempest

The biomarker results presented from the TPST-1120 Phase 1 clinical study demonstrate pharmacodynamic changes in circulating blood in patients who received clinical benefit from therapy that are consistent with blocking the activity of PPAR-.

Key Points: 
  • The biomarker results presented from the TPST-1120 Phase 1 clinical study demonstrate pharmacodynamic changes in circulating blood in patients who received clinical benefit from therapy that are consistent with blocking the activity of PPAR-.
  • As we advance the Tempest pipeline, we continue to generate results that validate and differentiate the novel approaches of our product candidates, said Tom Dubensky, Ph.D., president of Tempest.
  • These discoveries may enable us to identify patient populations in future clinical studies that are most likely to benefit from treatment with TPST-1120.
  • Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway.

Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Retrieved on: 
Monday, September 26, 2022
Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Optical, Adult, American Academy, Ocular hypertension, UBE, Health, Safety, Lens (anatomy), IOP, Risk, MD, FDA, Food, Prevalence, Glaucoma, Macular edema, Aphakia, CME, World Health Organization, Senior, Inc., Drainage, Achievement, Timolol, Severe cognitive impairment, EP2, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eye, OTC, API, Quigley, Uncertainty, Humour, General manager, Diagnosis, Research, Optic nerve, American Academy of Ophthalmology, Drug discovery, Disease, Field line, Pharmaceutical industry, House of Santen, Ophthalmology, QD

OMLONTI was launched in Japan as Eybelis ophthalmic solution 0.002% in November 2018, and was filed for marketing approval in Asian countries in stages.

Key Points: 
  • OMLONTI was launched in Japan as Eybelis ophthalmic solution 0.002% in November 2018, and was filed for marketing approval in Asian countries in stages.
  • We are very pleased that this ophthalmic solution has been approved for glaucoma in the U.S., following approvals in Japan and Asia.
  • We have high expectations that omidenepag isopropyl will provide a new treatment option for more patients suffering from glaucoma and ocular hypertension through Santen.
  • OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Vishay Intertechnology Wet Tantalum Capacitor Offers Industry-High Capacitance, Mechanical Robustness for Military and Avionics Systems

Retrieved on: 
Wednesday, May 25, 2022
DNA, Lead, EP2, Telecommunication, Vishay Intertechnology, Radar, ESR, VSH, Tin, Temperature, VDC, NYSE, GLOBE, Printed circuit board

Voltage ratings for the capacitor range from 25 VDC to 125 VDC.

Key Points: 
  • Voltage ratings for the capacitor range from 25 VDC to 125 VDC.
  • Offering robust mechanical performance, the capacitor features high vibration (high frequency: 20 g; random: 19.64 g) and mechanical shock (50 g) capabilities.
  • Vishay Intertechnology, Inc. is a Fortune 1,000 Company listed on the NYSE (VSH).
  • The DNA of tech is a trademark and SuperTan is a registered trademark of Vishay Intertechnology.